Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in type 2 diabetes mellitus
NCT07394114Phase 3Recruiting
- Sponsor
- Huadong Medicine
- Start
- Feb 2026
- Primary completion
- Aug 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of poterepatide in type 2 diabetes mellitus (T2DM), sponsored by Huadong Medicine. Started Feb 2026; status: recruiting.
02
Drugs
poterepatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07394114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394114.